Igm Biosciences (IGMS) has disclosed a new risk, in the Trade Secrets category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Igm Biosciences faces a significant business risk should it pursue federal funding for its research, as it would then be subject to the Bayh-Dole Act stipulations. This legislation grants the U.S. government certain rights to inventions developed with public funds, including the possibility of “march-in” rights, which allow the government to authorize third-party use of Igm Biosciences’ inventions without guaranteeing compensation. Additionally, the U.S. government’s preference for domestic manufacturing could constrain Igm Biosciences’ operational flexibility, potentially undermining its competitive edge and impacting its financial stability.
Overall, Wall Street has a Strong Buy consensus rating on IGMS stock based on 3 Buys and 1 Hold.
To learn more about Igm Biosciences’ risk factors, click here.